VNDA
NASDAQ · Biotechnology
Vanda Pharmaceuticals Inc
$7.12
-1.45 (-16.92%)
Financial Highlights (FY 2026)
Revenue
218.56M
Net Income
-20,779,812
Gross Margin
94.3%
Profit Margin
-9.5%
Rev Growth
-9.6%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 94.3% | 94.3% | 30.7% | 30.7% |
| Operating Margin | -20.5% | -18.4% | 14.8% | 14.7% |
| Profit Margin | -9.5% | -9.0% | 10.4% | 10.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 218.56M | 241.66M | 122.09M | 118.94M |
| Gross Profit | 206.12M | 227.91M | 37.47M | 36.50M |
| Operating Income | -44,717,144 | -44,499,590 | 18.10M | 17.45M |
| Net Income | -20,779,812 | -20,678,716 | 12.67M | 12.10M |
| Gross Margin | 94.3% | 94.3% | 30.7% | 30.7% |
| Operating Margin | -20.5% | -18.4% | 14.8% | 14.7% |
| Profit Margin | -9.5% | -9.0% | 10.4% | 10.2% |
| Rev Growth | -9.6% | -9.6% | +22.8% | +0.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.71M | 1.71M | 139.11M | 164.30M |
| Total Equity | 185.63M | 185.63M | 288.85M | 284.24M |
| D/E Ratio | 0.01 | 0.01 | 0.48 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -17,205,684 | -18,073,197 | 21.61M | 18.83M |
| Free Cash Flow | — | — | 20.08M | 12.24M |